MCM
CLDX icon

Moore Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Moore Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$2.23M – 502
2022
Q4 		$2.23M Buy
50,000
+20,007
+67% +$714K 0.05% 262
2022
Q3 		$843K Buy
29,993
+12,212
+69% +$374K 0.02% 423
2022
Q2 		$479K Hold
17,781
– – 0.01% 433
2022
Q1 		$606K Buy
+17,781
New +$568K 0.02% 451
2021
Q1 		– Sell
-95,000
Closed -$1.66M – 689
2020
Q4 		$1.66M Buy
+95,000
New +$1.71M 0.02% 372

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return